This resulted in unnecessary increase of treatment cost and potential health risks to individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency if G6PD testing was not performed prior to the treatment, which could lead to severe acute haemolytic anaemia [94]. The gene discussed is G6PD; the disease is G6PD deficiency.